Pre-clinical research organisation Biomodels has announced that it has successfully collaborated with ActoGeniX, a development stage biopharmaceutical company, in obtaining FDA approval for an Investigational New Drug (IND) application for AGO13, a novel therapeutic product for the treatment of oral mucositis in cancer patients.
The FDA approval permits ActoGenix to initiate a phase 1b clinical trial in six major oncology centres in the US. AGO13 could become the first approved therapy for oral mucositis in patients undergoing treatment of solid tumours or head/neck cancers, according to A…
Further information:
Related posts:
- New Caphosol study shows reduction in severity and duration of Oral Mucositis
- Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401
- The effect of transdermal estradiol or oral conjugated oestrogen and fenretinide versus placebo on haemostasis and cardiovascular risk biomarkers in a randomised breast cancer chemoprevention trial
- Cytokines levels, Severity of acute mucositis and the need of PEG tube installation during chemo-radiation for head and neck cancer – a prospective pilot study
- A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899
Posted in